Simulations Plus Inc (SLP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Simulations Plus Inc (SLP) has a cash flow conversion efficiency ratio of 0.048x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.41 Million) by net assets ($133.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SLP days of operational coverage to measure how many days the company can operate on defensive assets alone.
Simulations Plus Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Simulations Plus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Simulations Plus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Simulations Plus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Wanlin Modern Logistic
SHG:603117
|
0.017x |
|
Zoneco Group Co Ltd
SHE:002069
|
0.203x |
|
Jiangsu Xinri E-Vehicle Co Ltd
SHG:603787
|
0.161x |
|
Steelcast Limited
NSE:STEELCAS
|
0.123x |
|
Egis Technology
TWO:6462
|
0.002x |
|
Zhejiang Dayang Biotech Group Co
SHE:003017
|
0.001x |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
-0.076x |
|
ITAFOS INC. ON
F:82E
|
0.003x |
Annual Cash Flow Conversion Efficiency for Simulations Plus Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Simulations Plus Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Simulations Plus Inc (SLP) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $124.80 Million | $18.13 Million | 0.145x | +98.92% |
| 2024-08-31 | $182.43 Million | $13.32 Million | 0.073x | -43.20% |
| 2023-08-31 | $170.03 Million | $21.86 Million | 0.129x | +28.00% |
| 2022-08-31 | $178.25 Million | $17.90 Million | 0.100x | -13.30% |
| 2021-08-31 | $165.78 Million | $19.20 Million | 0.116x | +65.64% |
| 2020-08-31 | $156.04 Million | $10.91 Million | 0.070x | -77.36% |
| 2019-08-31 | $37.68 Million | $11.64 Million | 0.309x | +6.16% |
| 2018-08-31 | $31.92 Million | $9.29 Million | 0.291x | +9.15% |
| 2017-08-31 | $25.80 Million | $6.88 Million | 0.267x | +11.89% |
| 2016-08-31 | $22.73 Million | $5.42 Million | 0.238x | -34.79% |
| 2015-08-31 | $19.53 Million | $7.13 Million | 0.365x | +6.26% |
| 2014-08-31 | $15.44 Million | $5.31 Million | 0.344x | +91.08% |
| 2013-08-31 | $14.24 Million | $2.56 Million | 0.180x | -28.00% |
| 2012-08-31 | $15.14 Million | $3.78 Million | 0.250x | +0.29% |
| 2011-08-31 | $14.04 Million | $3.50 Million | 0.249x | +11.86% |
| 2010-08-31 | $13.05 Million | $2.91 Million | 0.223x | -5.50% |
| 2009-08-31 | $10.57 Million | $2.49 Million | 0.236x | -5.64% |
| 2008-08-31 | $9.92 Million | $2.48 Million | 0.250x | -35.39% |
| 2007-08-31 | $7.66 Million | $2.96 Million | 0.387x | +90.98% |
| 2006-08-31 | $5.67 Million | $1.15 Million | 0.202x | -31.56% |
| 2005-08-31 | $4.86 Million | $1.44 Million | 0.296x | +128.72% |
| 2004-08-31 | $4.45 Million | $575.05K | 0.129x | -21.73% |
| 2003-08-31 | $3.28 Million | $541.85K | 0.165x | +14.24% |
| 2002-08-31 | $767.88K | $111.07K | 0.145x | -85.99% |
| 2001-08-31 | $282.97K | $292.10K | 1.032x | +239.14% |
| 2000-08-31 | $486.07K | $147.95K | 0.304x | +152.85% |
| 1999-08-31 | $740.66K | $89.16K | 0.120x | +111.96% |
| 1998-08-31 | $1.28 Million | $-1.29 Million | -1.007x | -141.11% |
| 1997-08-31 | $3.35 Million | $-1.40 Million | -0.418x | -183.51% |
| 1996-08-31 | $200.00K | $100.00K | 0.500x | -- |
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans… Read more